Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1812
http://purl.obolibrary.org/obo/NCIT_C1812
|
|---|---|
| Preferred Name | Yttrium Y-90 Ibritumomab Tiuxetan |
| Definitions |
A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A radioimmunotherapeutic agent consisting of a murine monoclonal anti-CD20 antibody (ibritumomab) linked by the chelator tiuxetan to the radioisotope yttrium-90 (Y 90). Yttrium Y 90 ibritumomab tiuxetan binds to and specifically delivers beta radiation to CD20-expressing tumor cells, thereby minimizing the systemic effects of radiation. |
|---|---|
| prefLabel | Yttrium Y-90 Ibritumomab Tiuxetan
|
| label | Yttrium Y-90 Ibritumomab Tiuxetan
|
| PDQ_Closed_Trial_Search_ID | 38483
|
| code | C1812
|
| Has_Target | |
| prefixIRI | NCIT:C1812
|
| in_subset |
See more
See less
|
| Display_Name | Yttrium Y-90 Ibritumomab Tiuxetan
|
| Preferred_Name | Yttrium Y-90 Ibritumomab Tiuxetan
|
| FDA_UNII_Code | QA846JAV5B
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Yttrium Y-90 Ibritumomab Tiuxetan
|
| NSC Number | 710085
|
| NCI_Drug_Dictionary_ID | 38483
|
| Legacy Concept Name | Y_90_Ibritumomab_Tiuxetan
|
| type | |
| ALT_DEFINITION | A radiolabeled monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment of other types of B-cell tumors. It is made up of the monoclonal antibody ibritumomab plus the radioisotope yttrium Y 90. It binds to the protein called CD20, which is found on B cells. The radiation in the yttrium Y 90 may kill the cancer cells. Y 90 ibritumomab tiuxetan is a type of radiopharmaceutical.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38483
|
| Accepted_Therapeutic_Use_For | Non-Hodgkin's Lymphoma
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
|
| UMLS_CUI | C0879283
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |